Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B C Cho

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
ESMO Open|March 11, 2026
Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057]J B Lee, K H Kim, S Yoon, et al.
ESMO Open|October 26, 2024
Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinomaM H Hong, S Park, T Vo, et al.
ESMO Open|January 28, 2026
Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancerJ B Lee, K H Kim, S Yoon, et al.
The Annals of Thoracic Surgery|July 30, 2014
Long-term outcome after resection of non-small cell lung cancer invading the thoracic inletStéphane Collaud, Tiago Machuca, Olaf Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLCT S K Mok, G Lopes, B C Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2020
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancerR Perets, J Bar, D W Rasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinomaH R Kim, S M Lim, H J Kim, et al.
Oncogene|January 17, 2017
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibitionH S Kim, M Jung, H N Kang, et al.
The Lancet. Oncology|April 16, 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialDavid Planchard, Tae Min Kim, Julien Mazieres, et al.
ESMO Open|June 29, 2023
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinomaB C Cho, K Penkov, I Bondarenko, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
ESMO Open|March 11, 2026
Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057]J B Lee, K H Kim, S Yoon, et al.
ESMO Open|October 26, 2024
Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinomaM H Hong, S Park, T Vo, et al.
ESMO Open|January 28, 2026
Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancerJ B Lee, K H Kim, S Yoon, et al.
The Annals of Thoracic Surgery|July 30, 2014
Long-term outcome after resection of non-small cell lung cancer invading the thoracic inletStéphane Collaud, Tiago Machuca, Olaf Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLCT S K Mok, G Lopes, B C Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2020
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancerR Perets, J Bar, D W Rasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinomaH R Kim, S M Lim, H J Kim, et al.
Oncogene|January 17, 2017
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibitionH S Kim, M Jung, H N Kang, et al.
The Lancet. Oncology|April 16, 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialDavid Planchard, Tae Min Kim, Julien Mazieres, et al.
ESMO Open|June 29, 2023
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinomaB C Cho, K Penkov, I Bondarenko, et al.
Pageof 8